ArticleCureus2026
Antiepileptic Drug-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Case Series.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
backgroundDrug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe cutaneous adverse drug reaction with multisystem involvement frequently triggered by aromatic antiepileptic drugs (AED) like phenytoin, carbamazepine, etc. The pathogenesis is due to reactive metabolites and the immune reaction of delayed-type hypersensitivity. This case series addresses the key clinical presentation with pharmacological and pharmacovigilance aspects of the DRESS syndrome. METHODOLOGY: This case series describes seven cases of AED-induced DRESS syndrome, assessed with Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria from a tertiary care teaching hospital in Tamil Nadu. Clinical presentation, laboratory parameters, causality assessment (WHO-UMC, Naranjo, Liverpool), preventability assessment (Modified Schumock Thornton), and severity grading (Hartwig-Siegel scale) were recorded. All assessment tools used are open access and properly cited.
resultsPhenytoin was the most common causative agent, followed by oxcarbazepine, valproate, and levetiracetam. Clinical presentation varied from five to 28 days of drug exposure. All cases were diagnosed to have
conclusionsAED-induced DRESS poses a significant pharmacological challenge due to its unpredictable immunopathogenesis and genetic predisposition. Pharmacovigilance strategies and early clinical recognition by recognizing subtle laboratory parameters are essential to mitigate potential risks. Future research should focus on identifying biomarkers, optimizing drug selection, and implementing structured monitoring in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.